Ontology highlight
ABSTRACT:
SUBMITTER: Vasan N
PROVIDER: S-EPMC7173400 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
Vasan Neil N Razavi Pedram P Johnson Jared L JL Shao Hong H Shah Hardik H Antoine Alesia A Ladewig Erik E Gorelick Alexander A Lin Ting-Yu TY Toska Eneda E Xu Guotai G Kazmi Abiha A Chang Matthew T MT Taylor Barry S BS Dickler Maura N MN Jhaveri Komal K Chandarlapaty Sarat S Rabadan Raul R Reznik Ed E Smith Melissa L ML Sebra Robert R Schimmoller Frauke F Wilson Timothy R TR Friedman Lori S LS Cantley Lewis C LC Scaltriti Maurizio M Baselga José J
Science (New York, N.Y.) 20191101 6466
Activating mutations in <i>PIK3CA</i> are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed <i>PIK3CA</i>-mutant cancer genomes and observed the presence of multiple <i>PIK3CA</i> mutations in 12 to 15% of breast cancers and other tumor types, most of which (95%) are double mutations. Double <i>PIK3CA</i> mutations are in cis on the same allele and result ...[more]